Valuation: Regencell Bioscience Holdings Limited

Capitalization 1.37TCr 1.15TCr 1.05TCr 1TCr 1.86TCr 1,24300Cr 1.93TCr 12TCr 4.85TCr 60TCr 5.14TCr 5.03TCr 2,13800Cr P/E ratio 2024
-10.2x
P/E ratio 2025 -2,351x
Enterprise value 1.37TCr 1.15TCr 1.05TCr 1TCr 1.86TCr 1,24300Cr 1.93TCr 12TCr 4.85TCr 60TCr 5.14TCr 5.03TCr 2,13800Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
11.18%
Yield 2024 *
-
Yield 2025 -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.78%
1 week-2.00%
Current month+10.90%
1 month-39.47%
3 months+112.86%
6 months+98.39%
Current year+31.98%
More quotes
1 week 24.62
Extreme 24.6248
29
1 month 20.81
Extreme 20.81
50.22
Current year 20.5
Extreme 20.5
69
1 year 0.09
Extreme 0.0928
83.6
3 years 0.08
Extreme 0.0797
83.6
5 years 0.08
Extreme 0.0797
83.6
10 years 0.08
Extreme 0.0797
83.6
More quotes
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2014
Chief Operating Officer 49 01/08/2021
Director TitleAgeSince
Director/Board Member 49 28/12/2023
Director/Board Member 54 01/07/2021
Director/Board Member 65 13/12/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.78%-2.00%+26,549.04%+3,410.45% 1.35TCr
-0.27%-2.61%-14.57%-6.15% 4.68TCr
-1.43%+1.12%+56.09%+40.18% 3.92TCr
+4.55%+13.30%+33.18%+51.67% 3.29TCr
+2.76%-16.68%-7.43%-16.34% 3.18TCr
-0.77%-0.43%+129.30%+283.13% 1.88TCr
-2.16%-9.83%+49.77%+135.13% 1.53TCr
Average +0.64%-1.82%+3,827.91%+556.87% 2.83TCr
Weighted average by Cap. +0.73%-1.15%+1,831.19%+281.38%
See all sector performances

Financials

2024 2025
Net sales - -
Net income -43.02L -36.14L -33.03L -31.47L -58.39L -39Cr -60.7L -3.84Cr -1.52Cr -19Cr -1.61Cr -1.58Cr -67Cr -35.84L -30.11L -27.52L -26.22L -48.65L -33Cr -50.58L -3.2Cr -1.27Cr -16Cr -1.34Cr -1.32Cr -56Cr
Net Debt -78.75L -66.17L -60.48L -57.61L -1.07Cr -71Cr -1.11Cr -7.04Cr -2.79Cr -34Cr -2.95Cr -2.89Cr -122.89Cr -43.53L -36.57L -33.42L -31.84L -59.08L -39Cr -61.42L -3.89Cr -1.54Cr -19Cr -1.63Cr -1.6Cr -68Cr
More financial data * Estimated data
Logo Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Employees
10
More about the company
Date Price Change Volume
09/26/09 27.72 $ +1.78% 1,12,062
06/26/06 27.23 $ +8.62% 1,18,788
05/26/05 25.07 $ -11.66% 1,18,791
04/26/04 28.38 $ -0.25% 1,45,111
03/26/03 28.45 $ +0.60% 1,76,966

Delayed Quote Nasdaq, February 10, 2026 at 02:30 am IST

More quotes